	US 12,403,124 B2
	Central nervous system health supplement
William B. Coe, Wrightwood, CA (US)
Filed by William B. Coe, Wrightwood, CA (US)
Filed on Dec. 13, 2021, as Appl. No. 17/644,069.
Claims priority of provisional application 63/211,420, filed on Jun. 16, 2021.
Claims priority of provisional application 63/131,591, filed on Dec. 29, 2020.
Prior Publication US 2022/0202766 A1, Jun. 30, 2022
Int. Cl. A61K 31/352 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 31/197 (2006.01); A61K 31/202 (2006.01); A61K 31/405 (2006.01); A61K 31/575 (2006.01); A61K 31/685 (2006.01); A61K 31/706 (2006.01); A61K 36/42 (2006.01); A61K 36/79 (2006.01); A61K 38/06 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01)

CPC A61K 31/352 (2013.01) [A61K 9/006 (2013.01); A61K 9/205 (2013.01); A61K 9/2068 (2013.01); A61K 31/197 (2013.01); A61K 31/202 (2013.01); A61K 31/405 (2013.01); A61K 31/575 (2013.01); A61K 31/685 (2013.01); A61K 31/706 (2013.01); A61K 36/42 (2013.01); A61K 36/79 (2013.01); A61K 38/063 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01)]

15 Claims

1. A composition comprising:

sterubin; and

a pharmaceutically or physiologically-acceptable carrier;

wherein the composition is in a form adapted for sublingual administration of a dosage of the composition of 300 mg;

wherein the composition contains:

sterubin-bio-concentrated, yerba santa (11.2 wt. %);

gamma aminobutyric acid (10.7 wt. %);

tauroursodeoxycholic acid (10.7 wt. %);

glutathione (9.7 wt. %);

nicotinamide mononucleotide (9.5 wt. %);

alpha-glyceryl phosphorylcholine (8.5 wt. %);

5-hydroxytryptophan (5.5 wt. %);

phosphatidylserine (4.8 wt. %);

star anis (2.5 wt. %);

omega oil (11.5 wt. %);

glycerin (11.4 wt. %);

monk fruit (2.8 wt. %); and

magnesium stearate (1.2 wt. %).